SCHEMBL7021145

SCHEMBL7021145

COc1cccc(CNc2ccc3c(c2)ncn3-c2ccnc(N[C@@H](C)c3ccccc3)n2)c1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LCK P06239 12/20 0.61
JAK2 O60674 1/20 0.53
JAK3 P52333 1/20 0.53
KDM4E B2RXH2 2/20 0.52
ALDH1A1 P00352 2/20 0.52
NPC1 O15118 1/20 0.52
ALOX15 P16050 1/20 0.52
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HSD17B10 Q99714 1/20 0.52
KIT P10721 1/20 0.48
FLT3 P36888 1/20 0.48
MAPT P10636 2/20 0.47
HPGD P15428 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
GAA P10253 1/20 0.45
IDH1 O75874 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7019330 0.94 LCK (0.63) LCKJAK2JAK3KDM4EALDH1A1
SCHEMBL7593220 0.92 LCK (0.63) LCKJAK2JAK3KDM4EALDH1A1
SCHEMBL7020378 0.92 LCK (0.63) LCKJAK2JAK3KDM4EALDH1A1
SCHEMBL7594389 0.91 LCK (0.71) LCKJAK2JAK3KDM4EALDH1A1
SCHEMBL7017436 0.91 LCK (0.71) LCKJAK2JAK3KDM4EALDH1A1
SCHEMBL7590386 0.89 KIT (0.64) LCKJAK2JAK3KDM4EALDH1A1
SCHEMBL7016843 0.89 KIT (0.64) LCKJAK2JAK3KDM4EALDH1A1
SCHEMBL7025234 0.87 LCK (0.59) LCKJAK2JAK3KDM4EALDH1A1
SCHEMBL7020148 0.87 LCK (0.59) LCKJAK2JAK3KDM4EALDH1A1
SCHEMBL7589298 0.87 LCK (0.59) LCKJAK2JAK3KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1206265-B1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2003-11-12 EP disclosed
US-6498165-B1 PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS MERCK & CO., INC. 2002-12-24 US disclosed
EP-1206265-A4 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2002-08-07 EP disclosed
EP-1206265-A1 SRC KINASE INHIBITOR COMPOUNDS Merck & Co., Inc. (US) 2002-05-22 EP disclosed
WO-2001000213-A1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO., INC. (US) 2001-01-04 WO disclosed